Octagon Capital Advisors LP Acquires New Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Octagon Capital Advisors LP acquired a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 1,370,000 shares of the specialty pharmaceutical company's stock, valued at approximately $11,604,000. KalVista Pharmaceuticals comprises 1.9% of Octagon Capital Advisors LP's investment portfolio, making the stock its 22nd biggest position. Octagon Capital Advisors LP owned approximately 2.77% of KalVista Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of KALV. Aquatic Capital Management LLC purchased a new stake in KalVista Pharmaceuticals during the fourth quarter valued at approximately $44,000. Tower Research Capital LLC TRC lifted its holdings in shares of KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after purchasing an additional 5,502 shares during the last quarter. Legal & General Group Plc boosted its position in shares of KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after purchasing an additional 1,494 shares in the last quarter. Martin Worley Group purchased a new position in KalVista Pharmaceuticals during the 4th quarter worth $86,000. Finally, China Universal Asset Management Co. Ltd. increased its position in KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after buying an additional 2,043 shares in the last quarter.

Wall Street Analysts Forecast Growth

KALV has been the subject of several recent analyst reports. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. Jones Trading reiterated a "buy" rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Needham & Company LLC restated a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an "outperform" rating and a $19.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $24.83.

Insider Activity

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 3,125 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the transaction, the insider now directly owns 100,334 shares of the company's stock, valued at approximately $985,279.88. The trade was a 3.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Venrock Healthcare Capital Par purchased 100,000 shares of the company's stock in a transaction that occurred on Wednesday, February 12th. The shares were purchased at an average price of $9.23 per share, for a total transaction of $923,000.00. Following the transaction, the insider now owns 5,217,285 shares of the company's stock, valued at $48,155,540.55. This trade represents a 1.95% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 17,292 shares of company stock valued at $184,625 in the last ninety days. Insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Trading Up 2.4%

Shares of NASDAQ:KALV opened at $12.18 on Tuesday. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The company has a market cap of $605.54 million, a PE ratio of -3.35 and a beta of 0.05. The company's 50 day moving average is $12.05 and its 200 day moving average is $10.41.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.